TICKERNERD
Menu
SLDBSLDBHealthcare · Biotechnology

SLDB Stock Forecast: Solid Biosciences, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$6.20
−2.97% on the day

The 14 Wall Street analysts covering Solid Biosciences, Inc. hold a median 12-month price target of $19 — +198.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 42 of 100 as at 31 Oct 2026 — in the lower half.

Market cap
$664.8M
Ticker Nerd rank
42/ 100
Median analyst target
$19
Analysts covering
14
Revenue$0.0
Operating income−$57.4M
Net income−$54.8M
Free cash flow−$52.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+4.7%
1M
−14.2%
YTD
+9.9%
1Y
+16.8%
From 52W high
−44.4%
From 52W low
+57.8%
$4
$11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SLDB stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Solid Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
42/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
70
Revisions
61
Accruals
50
Growth
50
Size
49
Issuance
40
Value
38
Quality
36
Volatility
27

Momentum (70): The shares have been drifting up relative to others.

Volatility (27): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

SLDB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SLDB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20$25Jan 26Apr 26Jul 26Oct 26SLDBHigh $26Median $19Low $11

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
14 Buy0 Hold0 Sell
Low $11Median $19High $26

The green dot is the last close — the median target sits +198.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
15 Oct 2026UBSInitiatesBuy$20
16 Sept 2026RBC CapitalInitiatesOutperform$18
16 Sept 2026RBC CapitalInitiatesOutperform—
14 Sept 2026HC Wainwright & Co.ReiteratesBuy—
14 Sept 2026HC Wainwright & Co.ReiteratesBuy$25
27 Aug 2026Cantor FitzgeraldMaintainsOverweight—
27 Aug 2026Cantor FitzgeraldMaintainsOverweight$16 → $26
21 Aug 2026Truist SecuritiesMaintainsBuy—
21 Aug 2026Truist SecuritiesMaintainsBuy$16 → $20
3 June 2026HC Wainwright & Co.MaintainsBuy—
3 June 2026HC Wainwright & Co.MaintainsBuy$20 → $25
18 May 2026WedbushReiteratesOutperform—
13 May 2026Piper SandlerMaintainsOverweight—
13 May 2026WedbushMaintainsOutperform—
25 Mar 2026JP MorganMaintainsOverweight—
23 Mar 2026HC Wainwright & Co.ReiteratesBuy—
20 Mar 2026Chardan CapitalMaintainsBuy—
20 Mar 2026GuggenheimInitiatesBuy—
20 Mar 2026NeedhamReiteratesBuy—
12 Mar 2026Chardan CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

SLDB appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

SLDB vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, Solid Biosciences, Inc. returned +16.8% against +12.4% for the S&P 500, dividends included.

SLDB vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200Jan 26Apr 26Jul 26Oct 26SLDBS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SLDB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Solid Biosciences, Inc. (SLDB) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.2×

Cheaper than 73% of US stocks

Price / sales
—
Price / book
1.7×

Cheaper than 48% of US stocks

EV / EBITDA
−1.5×

Cheaper than 71% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−65.5%

Higher than 18% of US stocks

Return on assets
−36.4%

Higher than 12% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Solid Biosciences, Inc. (SLDB) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Solid Biosciences, Inc. has a market value of $664.8M and an enterprise value of $307.3M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$207.1M.

  • Free cash flow in the twelve months to 30 June 2026: −$187.8M.

  • Solid Biosciences, Inc. spent $13.6M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 105.1M.

  • Trailing P/E: 0.2×; forward P/E: −3.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Solid Biosciences, Inc. employs 121 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 31 Oct 2026

Data provided by Twelve Data

Peers

SLDB vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SLDBSolid Biosciences, Inc.$664.8M42
FDMT4D Molecular Therapeutics, Inc.$657.4M58
DSGNDesign Therapeutics, Inc.$658.7M60
IMMXImmix Biopharma, Inc.$636.7M36
AURAAura Biosciences, Inc.$634.8M46
LXRXLexicon Pharmaceuticals, Inc.$631.8M65
SLBTSL Science Holding Ltd.$672.9M0

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Solid Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SLDB news & analysis

Solid Biosciences Announces European Commission Orphan Designation for SGT-212 and Continued Progress in the FALCON Trial in Friedreich's Ataxia

GlobeNewsWire · 26 Oct 2026positive

The European Commission granted orphan designation to Solid Biosciences’ SGT-212 for Friedreich’s ataxia. In the ongoing Phase 1b FALCON trial, five participants had been dosed and SGT-212 was reported as well tolerated as of October 5, 2026; the company expects initial data in Q1 2027.

Why it matters — The designation and trial update provide news on SGT-212’s regulatory status and clinical development for Friedreich’s ataxia.

Solid Biosciences to Present Research Across Gene Therapy Development, Delivery and Manufacturing at ESGCT 2026

GlobeNewsWire · 20 Oct 2026positive

Solid Biosciences announced that seven abstracts have been accepted for poster presentation at the 33rd ESGCT Annual Congress, scheduled for October 27–30, 2026, in Hamburg. The presentations cover research across gene therapy development, delivery and manufacturing.

Why it matters — The accepted abstracts will give SLDB watchers an opportunity to learn about the company’s research at a gene and cell therapy conference.

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 1 Oct 2026neutral

Solid Biosciences announced the grant of 8,150 restricted stock units to one newly hired employee as an inducement award under Nasdaq Listing Rule 5635(c)(4).

Why it matters — Investors tracking SLDB would note this as a routine equity-based hiring incentive, providing insight into recent personnel additions without indicating company performance.

Solid Biosciences: A Funded Challenge To Duchenne Gene Therapy's Limitations

Seeking Alpha · 25 Sept 2026neutral

The article covers Solid Biosciences' SGT-003 gene therapy for Duchenne muscular dystrophy, highlighting its funded cash runway into mid-2028 and a strategy of building both biological and controlled functional evidence rather than relying solely on microdystrophin expression. It also discusses the company's competitive positioning against Sarepta and Regenxbio, which depends on achieving clinically meaningful differentiation in function, safety, and eligibility under time pressure from advancing rivals.

Why it matters — A SLDB watcher would care because the article frames the company's differentiated SGT-003 approach and funding runway as central to its ability to compete in the Duchenne gene therapy space against advancing rivals.

Solid Biosciences Inc. (SLDB) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Seeking Alpha · 10 Sept 2026neutral

Solid Biosciences Inc. (SLDB) presented at Citigroup's Biopharma Back to School Summit 2026, with a transcript of the presentation published by Seeking Alpha. The item covers the company's remarks at the investor conference.

Why it matters — A SLDB watcher would care because the presentation offers insight into the company's positioning and updates shared with investors at a major biopharma conference.

FAQ

Frequently asked questions about SLDB stock

What is the SLDB stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Solid Biosciences, Inc. have a median 12-month price target of $19, with estimates ranging from $11 to $26. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SLDB stock a buy right now?

Of the 14 analysts covering Solid Biosciences, Inc., 14 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Solid Biosciences, Inc. 42 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SLDB?

As at 31 Oct 2026, Solid Biosciences, Inc. ranks 42 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (70 of 100).

Will SLDB stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +198.4% from the last close, and Ticker Nerd's factor model ranks Solid Biosciences, Inc. 42 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SLDB stock forecast for 2030?

No analyst covering Solid Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SLDB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $26 over the next 12 months.

How has SLDB stock performed over the past year?

Solid Biosciences, Inc. returned +16.8% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Solid Biosciences, Inc. do?

Solid Biosciences Inc. is a precision genetic medicine company focused on developing gene therapy candidates for rare neuromuscular and cardiac diseases.

What is the latest news on SLDB?

The most recent item we track (GlobeNewsWire, 26 Oct 2026): "Solid Biosciences Announces European Commission Orphan Designation for SGT-212 and Continued Progress in the FALCON Trial in Friedreich's Ataxia". The European Commission granted orphan designation to Solid Biosciences’ SGT-212 for Friedreich’s ataxia. In the ongoing Phase 1b FALCON trial, five participants had been dosed and SGT-212 was reported as well tolerated as of October 5, 2026; the company expects initial data in Q1 2027.

Company

About Solid Biosciences, Inc.

Solid Biosciences Inc. is a precision genetic medicine company focused on developing gene therapy candidates for rare neuromuscular and cardiac diseases. Solid Biosciences Inc. advances a pipeline that includes programs for Duchenne muscular dystrophy, Friedreich’s ataxia, catecholaminergic polymorphic ventricular tachycardia, and certain forms of dilated cardiomyopathy. Its work centers on addressing severe genetic disorders through targeted therapies designed to act on the underlying disease biology rather than on symptoms alone. The company serves the biotechnology and rare-disease markets, where its research and clinical development efforts are aimed at conditions with significant unmet medical need. Headquartered in Charlestown, Massachusetts, Solid Biosciences Inc. operates as a life sciences company with a focus on translating genetic science into treatments for patients with serious inherited diseases.

CEO Mr. Alexander G. Cumbo · 121 employees · United States · https://www.solidbio.com